105 results
8-K
EX-99.1
OCGN
Ocugen Inc
22 Dec 20
Ocugen and Bharat Biotech TO Co-DEVELOP COVAXIN™, a Whole-Virion Inactivated COVID-19 Vaccine, for the US market
9:08am
in vaccine innovation, today announced that the companies have signed a binding letter of intent (LOI) to co-develop Bharat Biotech’s COVID-19 vaccine … caused unmatched devastation to individual patients and to the world. It is going to take the kind of unmatched collaboration and innovation
8-K
EX-99.1
OCGN
Ocugen Inc
12 Jan 22
Other Events
4:05pm
in vaccine innovation and developer of vaccines for infectious diseases, today announced results from a study conducted at Emory University demonstrating … of Bharat Biotech said, “We are in a continuous state of innovation and product development for COVAXIN™. The positive neutralization responses against
8-K
EX-99.1
OCGN
Ocugen Inc
22 Feb 22
Other Events
7:36am
track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more … , and vaccine supply and distribution.
Having delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation
8-K
EX-99.1
OCGN
Ocugen Inc
17 Aug 22
Other Events
4:03pm
Courageous Innovation August 2022 NASDAQ: OCGN
Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning … an Impact Through Courageous Innovation 3 Mission: At Ocugen, we are developing novel solutions to medical challenges, approaching healthcare innovation
8-K
EX-99.1
OCGN
Ocugen Inc
26 Nov 21
Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating
7:38am
, please visit www.ocugen.com.
About Bharat Biotech
Bharat Biotech has established an excellent track record of innovation with more than 145 global … delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1
8-K
EX-99.1
d5wn7matb
26 Aug 22
Other Events
5:04pm
8-K
EX-99.1
7kxyflsmzkpkqed
16 Aug 22
Other Events
4:09pm
8-K
EX-99.1
0wf5c0rdrj kr
22 Apr 21
Other Events
6:01am
8-K
EX-99.1
b7alr mpz6
27 Oct 21
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
8:10am
8-K
EX-99.1
yj21n
18 Mar 24
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
8:54am
8-K
EX-99.1
ars17jk7d1nttp0zdb3
3 Mar 21
Other Events
9:55am
8-K
EX-99.1
plb2kc gp3
6 Jul 21
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
6:02am
8-K
EX-99.1
2rj mnml5l
10 Jan 22
Other Events
4:07pm
8-K
EX-99.1
3piqbyenq8v
18 Apr 18
Histogenics Corporation Announces the Appointment of Susan Washer
12:00am
8-K
EX-99.1
8kqutyoszydhuju
21 Feb 24
Regulation FD Disclosure
11:22am
8-K
EX-99.1
foqd2
30 Dec 21
Other Events
4:27pm
8-K
EX-99.1
tbn7hccbcbrybjvm3
14 Sep 22
Ocugen Announces Publication of a Comprehensive Review of BBV152 In Frontiers In Immunology
4:05pm
8-K
EX-99.1
0j5u0w zitohczwio
5 May 23
Other Events
8:16am
8-K
EX-99.1
4on dus2n
24 May 22
Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
7:36am
8-K
EX-99.2
89x4fg
6 May 22
Ocugen Provides Business Update and First Quarter 2022 Financial Results
6:44am